MedTrace Logo

Analgesia aNd caNcer recUrrence Lung cAncer Resection

NCT04656769 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 382

Last updated 2020-12-21

No results posted yet for this study

Summary

The choice of analgesia after cancer surgery may play a role in the onset of recurrence, particularly opioids seem to play a role in the immune system by promoting cancer cell proliferation and migration. Based on this consideration, our aim was to assess the impact of perioperative analgesia's choice on cancer recurrence after curative surgery for Stage I Non-Small Cell Lung Cancer. The investigators retrospectively reviewed the records of patients who underwent lung resection for Stage I NSCLC between January 2005 and December 2012. Patients received analgesia either by peridural (PERI group) or, in case of patient refusal or failure in catheter positioning, intravenous analgesia with opioids (EV group). Follow-up was concluded in August 2019. The five-year cumulative incidence of recurrence and the overall survival were evaluated and adjusted with a propensity score matching methodology.

Conditions

  • Recurrence Tumor
  • Opioid Use, Unspecified
  • Analgesia
  • Thoracic Surgery

Interventions

PROCEDURE

Peridural analgesia

We attempted to evaluate the effectiveness of peridural analgesia through cancer survival and recurrence outcomes.

Sponsors & Collaborators

  • University of Turin, Italy

    lead OTHER

Principal Investigators

  • Luca Brazzi, Professor · University of Torino

  • Giulio L Rosboch, MD · A.O.U. Città della Salute e della Scienza

  • Ilaria De Domenici, MD · University of Torino

  • Edoardo Ceraolo, MD · A.O.U. Città della Salute e della Scienza

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-17
Primary Completion
2020-04-01
Completion
2020-11-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04656769 on ClinicalTrials.gov